In a report published Friday, Deutsche Bank upgraded its rating on Mednax MD from Sell to Hold, and raised its price target from $65.00 to $76.00.
Deutsche Bank noted, “MD's last two quarters have significantly allayed our concerns about a steeper slow-down in NICU trends. The combination of better-than-expected NICU volumes and stronger margins force us to reconsider our more cautious view on MD's earnings power. We move to Hold (from Sell), and raise our PT to $76 ($65) on higher estimates and our year-end process to roll-forward valuations off the new out-year (2014).”
Mednax closed on Thursday at $73.41.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in